Kevin Bitterman has left Polaris Partners, where he spent more than a decade helping build biotech companies, to become a partner at another Boston-area life sciences venture firm, Atlas Venture. Bitterman was the founding CEO of Editas Medicine (NASDAQ: [[ticker:EDIT]]), Visterra, and Morphic Therapeutic, helped co-found Genocea Biosciences (NASDAQ: [[ticker:GNCA]]), and is also the chairman of the New England Venture Capital Association. Here’s more on the hire from Atlas partner Bruce Booth’s blog.
Author: Ben Fidler
Ben is former Xconomy Deputy Editor, Biotechnology. He is a seasoned business journalist that comes to Xconomy after a nine-year stint at The Deal, where he covered corporate transactions in industries ranging from biotech to auto parts and gaming. Most recently, Ben was The Deal’s senior healthcare writer, focusing on acquisitions, venture financings, IPOs, partnerships and industry trends in the pharmaceutical, biotech, diagnostics and med tech spaces. Ben wrote features on creative biotech financing models, analyses of middle market and large cap buyouts, spin-offs and restructurings, and enterprise pieces on legal issues such as pay-for-delay agreements and the Affordable Care Act. Before switching to the healthcare beat, Ben was The Deal's senior bankruptcy reporter, covering the restructurings of the Texas Rangers, Phoenix Coyotes, GM, Delphi, Trump Entertainment Resorts and Blockbuster, among others. Ben has a bachelor’s degree in English from Binghamton University.
View all posts by Ben Fidler